Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:40 AM
Ignite Modification Date:
2025-12-25 @ 12:40 AM
NCT ID:
NCT01638767
Eligibility Criteria:
Inclusion Criteria:
* Signed consent form
* Age 18 or above at the time of selection
* In Vitro Fertilization referral
* Complete and normal pre-In Vitro Fertilization check-up
* Long protocol prescription
* No previous participation in the project during a previous cycle
Exclusion Criteria:
* Simultaneous participation in another interventional research project
* Contraindications of being pregnant or carrying a pregnancy to full term
* Contraindications of taking standard medication for long protocol
* Contraindications of taking Marvelon or using NuvaRing (Uncontrolled high blood pressure, uncontrolled diabetes, active hepatic infection, benign or malignant hepatic tumors, diagnosed breast cancer, diagnosed or suspected estrogen-dependant neoplasia, ocular or suspected lesion, history of thrombophlebitis, cardiac arrest, coronary heart disease.)
* Patient presenting vaginal abnormalities could be unable to insert the NuvaRing
* Cervicitis, vaginitis, erosio portionis bleeding, cervical prolapse, cystocele, rectocele, severe or chronic constipation, dyspareunia or other problems with sexual intercourse
* Patient having received research medication 30 days before visit 1
* Patient is unable to communicate adequately with researchers
* Patient is incapable of giving informed consent
* Any ovarian or abdominal abnormalities could interfere with an adequate sonographic evaluation
* Use of the following medication:
* Clonidine
* Anticoagulants (before the anovulant pre-treatment)
* Anticonvulsants
* Oral or insulin hypoglycemia drugs
* Hypertension drugs (beta blockers)
* Aminocaproic acid
* Beta mimetics (isoproterenol)
* Prednisone
* Ciclosporin
* Meperidine
* Phenothiazine and reserpine
* Chlordiazepoxide, Lorazepam, Oxazepam, Diazepam (during the anovulant pre-treatment)
* Theophylline
* Clomipramine
* Vitamin B12
* Hypericum perforatum-based products
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Maximum Age:
43 Years
Study:
NCT01638767
Study Brief:
Protocol Section:
NCT01638767